相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
Louisa Maria Bulirsch et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2022)
Brolucizumab-early real-world experience: BREW study
Ashish Sharma et al.
EYE (2021)
Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
Ana Bety Enriquez et al.
JAMA OPHTHALMOLOGY (2021)
Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study
Ichiro Maruko et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab Post Hoc Review of HAWK and HARRIER
Jordi Mones et al.
OPHTHALMOLOGY (2021)
Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
Christof Haensli et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment
Caroline R. Baumal et al.
OPHTHALMOLOGY RETINA (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group
Richard F. Spaide et al.
OPHTHALMOLOGY (2020)
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
Ashish Sharma et al.
EYE (2020)
Brolucizumab-key learnings from HAWK and HARRIER
Ashish Sharma et al.
EYE (2020)
Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors
Jakob Siedlecki et al.
SCIENTIFIC REPORTS (2020)
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
Caroline R. Baumal et al.
OPHTHALMOLOGY (2020)
Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity
Srinivas Sai A. Kondapalli
JAMA OPHTHALMOLOGY (2020)
Brolucizumab: the road ahead
Ashish Sharma et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents
Rebecca N. Evans et al.
JAMA OPHTHALMOLOGY (2020)
Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?
Philip J. Rosenfeld et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2020)
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Federico Ricci et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
Jaycob Avaylon et al.
INTERNATIONAL MEDICAL CASE REPORTS JOURNAL (2020)
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration
Emily Li et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials
Glenn J. Jaffe et al.
OPHTHALMOLOGY (2019)
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
Robyn H. Guymer et al.
OPHTHALMOLOGY (2019)
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Sharon D. Solomon et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
SriniVas R. Sadda et al.
OPHTHALMOLOGY (2018)
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
Rufino Silva et al.
OPHTHALMOLOGY (2018)
A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab
S. R. Rufai et al.
EYE (2017)
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials
Juan E. Grunwald et al.
OPHTHALMOLOGY (2017)
Geo-Epidemiology of Age-Related Macular Degeneration: New Clues Into the Pathogenesis
Michele Reibaldi et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Juan E. Grunwald et al.
OPHTHALMOLOGY (2014)
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop
DA Jabs et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2005)
分享论文
